23 September, 03:32
Based on application, the 3D bioprinting market is segmented into research applications and clinical applications. The research applications segment accounted for the larger share of the 3D bioprinting market in 2021. The market for research applications is further segmented into #drug research, regenerative medicine, and 3D cell culture. Among these, the drug research segment accounted for the largest share of the market in 2021, due to the growing adoption of 3D bioprinting technology by biopharmaceutical companies.
Get PDF Brochure: https://lnkd.in/dAPVWgSc
#3D #bioprinting #technolog
Get PDF Brochure: https://lnkd.in/dAPVWgSc
#3D #bioprinting #technolog
23 September, 02:54
Bonjour,
- FDA approves world’s costliest therapy, priced at US$ 3 million, from Bluebird bio.
- Mallinckrodt receives FDA approval to treat life-threatening liver condition.
- Novartis to move Supreme Court to secure validity of Gilenya patent.
- FDA issues Form 483 with 12 observations to Catalent’s Indiana site.
- BMS, AbbVie to lay off up to 360 employees in California.
- BMS’ Opdivo shows promise as adjuvant treatment for melanoma.
- EMA recommends AstraZeneca-Sanofi’s RSV drug for infants.
#Phispers This Week - PharmaCompass.com's Weekly News Recap
#Healthcare #pharmaceuti
- FDA approves world’s costliest therapy, priced at US$ 3 million, from Bluebird bio.
- Mallinckrodt receives FDA approval to treat life-threatening liver condition.
- Novartis to move Supreme Court to secure validity of Gilenya patent.
- FDA issues Form 483 with 12 observations to Catalent’s Indiana site.
- BMS, AbbVie to lay off up to 360 employees in California.
- BMS’ Opdivo shows promise as adjuvant treatment for melanoma.
- EMA recommends AstraZeneca-Sanofi’s RSV drug for infants.
#Phispers This Week - PharmaCompass.com's Weekly News Recap
#Healthcare #pharmaceuti
Bluebird ousts its own gene therapy approved last month as world’s costliest; Catalent hit by FDA’s Form 483 | Radio Compass Phisper
Exactly a month after Bluebird bio’s gene therapy Zynteglo became the most expensive treatment at US$ 2.8 million, a second therapy from the drugmaker has clinched that title. The drug – Skysona or eli-cel – approved by the US Food and Drug Administration (FDA) to treat a rare n...
https://lnkd.in/dkGiTYgm
23 September, 02:49
*In just a few decades, Algeria has become one of Africa's leading pharmaceutical producers. More than 2.5 billion euros worth of medicines were produced last year. Some 200 production units cover nearly 70% of the country's generic needs, and this self-sufficiency is good news for the country and the region, as the international market remains volatile. **
https://lnkd.in/eTE9f8zk
#africa #Healthcare #medicines #pharmaceutical #utano #algeria
https://lnkd.in/eTE9f8zk
#africa #Healthcare #medicines #pharmaceutical #utano #algeria
Algerian pharmaceutical boom: A step towards health & food security | Africanews
Algeria has become one of Africa's leading pharmaceutical producers. More than 2.5 billion euros worth of medicines were produced last year. Some 200 production units cover nearly 70% of the country's generic needs. Which is helping to provide health security in the country and region.
https://lnkd.in/eTE9f8zk
